ZYBERNO
Stock Report
Updated Sep 1, 2026

Schrodinger, Inc. (SDGR)

Healthcare • NASDAQ

$19.70
Schrödinger Inc. is an American computational drug discovery company headquartered in New York City that provides a physics-based software platform for drug discovery and materials science. The company's Maestro and FEP+ platforms use molecular simulation to predict how potential drug molecules will behave, helping pharmaceutical companies identify promising drug candidates more efficiently and with its own internal drug discovery programs.

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
28.0/100
POOR BUSINESS
Schrodinger, Inc. (SDGR) scores 28/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-47.4%)
Debt-to-Equity (Solvency Risk):AVERAGE (0.61x)
Operating Margin (Operational Efficiency):CRITICAL (-59.2%)
Return on Capital (Capital Efficiency):CRITICAL (-83.7%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Schrodinger, Inc. (SDGR) stock report — Zyberno Score 28/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, SDGR generated -$147.32M in Owner Earnings. Capital was deployed as follows: $3.35M invested in capital expenditures. Reinvestment rate: 3.7%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:19.70
Market Cap:$1.47B

Valuation Multiples (3)

P/B Ratio:4.47x
P/S Ratio:5.68x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$1.29B

Price Action & Momentum (3)

Momentum Percentile:23 / 100
% of 52-Week High:85.6%
B. Profitability Assessment

Return Metrics (5)

ROA:-23.7%
Reinvestment Rate:3.7%
Fundamental Growth Rate (g):-3.1%

Margin Analysis (3)

Operating Margin Ttm:-59.2%
Net Margin Ttm:-60.7%
Ebitda Margin:-57.0%

TTM Performance (3)

Gross Margin Ttm:56.9%
Operating Margin Ttm:-59.2%
Net Margin Ttm:-60.7%

Yield Metrics (2)

Earnings Yield:-$10.86
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:109.8%
Latest Earnings Filed:2026-08-05

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):13.8%

Earnings Growth (Linear) (1)

Net Income Growth Rate (Linear):-44.1%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.71x
Quick Ratio:2.71x
Cash Ratio:1.66x

Leverage Analysis (3)

Debt To Equity Ttm:0.61x
Debt-to-Equity Ratio:0.61x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:296,630,000.00
Cash And Cash Equivalents:287,853,000.00
Long Term Debt:$91.50M
Net Debt:-$179.87M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $259.04M
Linear Growth: 13.8%
📊 Click to view full SDGR Revenue analysis & methodology →
Cost Of Revenue Ttm:$111.72M

Profitability Breakdown (2)

Gross profit TTM: $147.31M
Linear Growth: 9.6%
📊 Click to view full SDGR Gross Profit analysis & methodology →
-$153.45M

Bottom Line Performance (3)

Net income TTM: -$157.32M
Linear Growth: -44.1%
📊 Click to view full SDGR Net Income analysis & methodology →
Income Before Tax:-$154.60M
Ebitda Ttm:-147,536,000.00

Operating Expenses (5)

Operating Expenses:300,756,000.00
R And D Expense:168,978,000.00
Sga Expense:90,047,000.00
Income Tax Expense:$2.40M
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:286.9%
Sga To Revenue Percentage:152.9%
Ebitda Margin:-57.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$640.39M
Current Assets:$470.48M
Ppe Net:0.00
Goodwill:4,791,000.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:311,438,000.00
Current Liabilities:173,845,000.00
Long Term Debt:$91.50M
Short Term Debt:$16.48M

Equity & Capital (3)

Equity:$328.96M
Retained Earnings:-$682.86M
Common Stock:500,000,000.00

Working Capital Items (3)

Accounts Receivable:21,391,000.00
Inventory:0.00
Accounts Payable:10,320,000.00

Special Items (2)

Contract Liabilities:104,773,000.00
Stock Based Compensation:8,794,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$145.00M-$148.35M

Investment Activities (2)

Investing Cash Flow:$44.60M
Capital Expenditures Ttm:3,353,000.00

Financing Activities (3)

Financing Cash Flow:$569.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:5,909,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-2.14
Eps diluted TTM: -$2.14
Linear Growth: -44.5%
📊 Click to view full SDGR EPS analysis & methodology →
Earnings Per Share Ttm:-$2.11

Revenue & Cash Per Share (2)

Sales Per Share Ttm:3.47
Operating Cash Flow Per Share:$0.19

Book Value & Capital (2)

Book Value Per Share:$4.40
Cash Per Share:3.85

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.39x
Working Capital Turnover Ttm:0.87x

Receivables Management (2)

Receivables Turnover Ttm:12.11x
Days Sales Outstanding Ttm:30.14

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:33.72
Cash Conversion Cycle:-1,002.57
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:50.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$147.32M

Damodaran Growth Analysis (2)

Reinvestment Rate:3.7%
Fundamental Growth Rate (g):-3.1%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (2)

Revenue Growth Rate (Linear):13.8%
Net Income Growth Rate (Linear):-44.1%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):9.6%
Book Value Growth Rate (Linear):-14.7%
C. Company Profile & Context

Corporate Information (6)

Symbol:SDGR
Company Name:Schrodinger, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:74.71M
Shares Outstanding Basic:74.71M
Shares Outstanding Diluted:75.77M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 01:28:58 UTC
Data Timestamp:2026-09-01T01:28:58.007203
Scroll to Top